Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Jul 25;2014(7):CD007533.
doi: 10.1002/14651858.CD007533.pub3.

Botulinum toxin for myofascial pain syndromes in adults

Adriana Soares  1 , Régis B Andriolo, Alvaro N Atallah, Edina M K da Silva
Affiliations

Botulinum toxin for myofascial pain syndromes in adults

Adriana Soares et al. Cochrane Database Syst Rev. .

Abstract

Background: This is an updated version of the original Cochrane review published in Issue 4, 2012. Myofascial pain syndrome (MPS) is a regional muscular pain syndrome characterised by the presence of trigger points, which are painful points in one or more muscles. The pain can be felt at the site where the trigger point is located or it can be felt away from that place when the muscle is pressed (referred pain). Botulinum toxin is a protein produced by the bacterium Clostridium botulinum and is a potent neurotoxin that eventually inhibits muscle contractions. It is capable of selectively weakening painful muscles and interrupting the pain cycle.

Objectives: To assess the effectiveness and safety of botulinum toxin A (BTXA) in the treatment of myofascial pain syndrome (MPS), excluding MPS in neck and head muscles.

Search methods: This is an updated version of the original Cochrane review published in Issue 4, 2012. The search strategy for the update was the same as in the original review and we searched CENTRAL in The Cochrane Library (2013, Issue 11 of 12), MEDLINE (Ovid) (2012 to 29 November 2013) and EMBASE (Ovid) (2012 to 27 November 2013). The search strategy was composed of terms for myofascial pain and botulinum toxin. For the original review, we also searched the Cochrane Pain, Palliative and Supportive Care (PaPaS) Review Group Specialised Register until December 2011, PubMed (from 1966 to 2011) and LILACS (from 1982 to 2011). There was no language restriction.

Selection criteria: We included randomised controlled trials (RCTs) involving botulinum toxin for treating participants with MPS. We excluded studies with MPS of the neck and head from this review as they have already been assessed in existing systematic reviews. We considered a diagnosis of MPS to be based on the identification of trigger points in the taut band through palpation of sensitive nodules, local twitch response and specific patterns of referred pain associated with each trigger point.

Data collection and analysis: Two review authors independently screened identified studies, extracted data, assessed trial quality and analysed results using the Cochrane PaPaS Review Group criteria.

Main results: Four studies with a total of 233 participants, comparing BTXA with placebo, met the inclusion criteria. In one study with 145 participants, significant improvement rates of pain intensity scores and duration of daily pain were demonstrated when comparing BTXA with placebo. The three other studies showed that there was no statistically significant difference between BTXA and placebo in pain intensity.

Authors' conclusions: Since the first publication of this review, no new studies were found. There is inconclusive evidence to support the use of botulinum toxin in the treatment of MPS based on data from four studies with a total of 233 participants, which we considered were of sufficient quality to be included in this review. Meta-analyses were not possible due to the heterogeneity between studies. We suggest that in future studies the same methodology to assess pain, a standardised dose of treatment, follow-up of at least four months (to observe the maximum and minimum curve of the drug effect) and appropriate data presentation should be used. More high-quality RCTs of botulinum toxin for treating MPS need to be conducted before firm conclusions on its effectiveness and safety can be drawn.

PubMed Disclaimer

Conflict of interest statement

None known.

Figures

1
1
Study flow diagram.
2
2
Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.
3
3
Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
See this image and copyright information in PMC

Update of

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

References to studies included in this review

De Andrés 2010 {published data only}
    1. De Andrés J, Adsuara VM, Palmisani S, Villanueva V, López-Alarcón MD. A double-blind, controlled, randomised trial to evaluate the efficacy of botulinum toxin for the treatment of lumbar myofascial pain in humans. Regional Anesthesia and Pain Medicine 2010;35(3):255-60. - PubMed
Göbel 2006 {published and unpublished data}
    1. Göbel H, Heinze A, Reichel G, Hefter H, Benecke R. Dysport myofascial pain study group. Efficacy and safety of a single botulinum type A toxin complex treatment (Dysport) for the relief of upper back myofascial pain syndrome: results from a randomised double-blind placebo-controlled multicentre study. Pain 2006;125(1-2):82-8. [PMID: ] - PubMed
Ojala 2006 {published data only}
    1. Ojala T, Arokoski JP, Partanen J. The effect of small doses of botulinum toxin A on neck-shoulder myofascial pain syndrome: a double-blind, randomised, and controlled crossover trial. Clinical Journal of Pain 2006;22(1):90-6. [PMID: ] - PubMed
    1. Ojala TA, Arokoski JP, Partanen JV. Needle-electromyography findings of trigger points in neck-shoulder area before and after injection treatment. Journal of Musculoskeletal Pain 2006;14(1):5-14.
    1. Ojala TA, Jurvelin JS, Partanen JV, Arokoski JP. Soft tissue stiffness before and after trigger point injections in neck-shoulder myofascial pain syndrome: a double-blind, randomized, and controlled crossover trial with botulinum toxin A and saline injections. Journal of Musculoskeletal Pain 2010;18(1):38-48. [DOI: 10.3109/10582450903496021] [EMBASE: 2010166918] - DOI
Qerama 2006 {published and unpublished data}
    1. Qerama E, Fuglsang-Frederiksen A, Kasch H, Bach FW, Jensen TS. A double-blind, controlled study of botulinum toxin A in chronic myofascial pain. Neurology 2006;67:241-5. [EMBASE: 44305406] - PubMed

References to studies excluded from this review

Benecke 2011 {published data only}
    1. Benecke R, Heinze A, Reichel G, Hefter H, Gobel H. Botulinum type A toxin complex for the relief of upper back myofascial pain syndrome: how do fixed-location injections compare with trigger point-focused injections? Pain Medicine 2011;12(11):1607-14. - PubMed
Cheshire 1994 {published data only}
    1. Cheshire WP, Abashian SW, Mann JD. Botulinum toxin in the treatment of myofascial pain syndrome. Pain 1994;59:65-9. - PubMed
Davis 2011 {published data only}
    1. Davis TL, Fang JY, Gill CE, Charles PD. A pilot trial of onabotulinumtoxinA for the treatment of cervicothoracic myofascial pain. Botulinum Journal 2011;2(1):6-15.
Esenyel 2007 {published data only}
    1. Esenyel M, Aldemir T, Gursoy E, Esenyel CZ, Demir S, Durmusoglu G. Myofascial pain syndrome: efficacy of different therapies. Journal of Back and Musculoskeletal Rehabilitation 2007;20(1):43-7.
Ferrante 2005 {published data only}
    1. Ferrante FM, Bearn L, Rothrock R, King L. Evidence against trigger point injection technique for the treatment of cervicothoracic myofascial pain with botulinum toxin type A. Anesthesiology 2005;103(2):377-83. - PubMed
Graboski 2005 {published data only}
    1. Graboski CL, Shaun Gray D, Burnham RS. Botulinum toxin A versus bupivacaine trigger point injections for the treatment of myofascial pain syndrome: a randomised double blind crossover study. Pain 2005;118(1-2):170-5. - PubMed
Kamanli 2005 {published data only}
    1. Kamanli A, Kaya A, Ardicoglu O, Ozgocmen S, Zengin FO, Bayik Y. Comparison of lidocaine injection, botulinum toxin injection, and dry needling to trigger points in myofascial pain syndrome. Rheumatology International 2005;25(8):604-11. [PMID: ] - PubMed
Lew 2008 {published data only}
    1. Lew HL, Lee EH, Castaneda A, Klima R, Date E. Therapeutic use of botulinum toxin type A in treating neck and upper-back pain of myofascial origin: a pilot study. Archives of Physical Medicine and Rehabilitation 2008;89(1):75-80. - PubMed
Porta 2000 {published data only}
    1. Porta M, Loiero M, Gamba M, Luccarelli G, Fornari M. The use of botuline A toxin in the treatment of myofascial painful syndromes. Riabilitazione 1999;32(2):49-55.
    1. Porta M, Loiero M, Gamba M. Botulinum toxin type a for myofascial pain syndromes: a comparative trial versus methylprednisolone. European Journal of Neurology 1999;6 Suppl 3:107.
    1. Porta M. A comparative trial of botulinum toxin type A and methylprednisolone for the treatment of myofascial pain syndrome and pain from chronic muscle spasm. Pain 2000;85(1-2):101-5. [EMBASE: 3011074] - PubMed
    1. Porta M. Botulinum toxin type A injections for myofascial pain syndrome and tension-type headache. European Journal of Neurology 1999;6 Suppl 4:S103-9.
Wheeler 1998 {published data only}
    1. Wheeler AH, Goolkasian P, Gretz SS. A randomised, double-blind, prospective pilot study of botulinum toxin injection for refractory, unilateral, cervicothoracic, paraspinal, myofascial pain syndrome. Spine 1998;23(15):1662-6. - PubMed

References to ongoing studies

Zeki 2010 {published data only}
    1. Zeki K, Mehmet O, Baki C, Engin D, Oguz T, Levent D, et al. The effectiveness of botulinum toxin type - A and prilocaine injections in myofascial pain syndrome. Arthritis and Rheumatism 2010;62 Suppl 10:114. [DOI: 10.1002/art.27883] - DOI

Additional references

Argoff 2002
    1. Argoff CE. A focused review on the use of botulinum toxins for neuropathic pain. Clinical Journal of Pain 2002;18 Suppl 6:S177-81. [PMID: 12569966] - PubMed
Baldry 2002
    1. Baldry P. Management of myofascial trigger point pain. Acupuncture in Medicine: Journal of the British Medical Acupuncture Society 2002;20(1):2-10. [PMID: ] - PubMed
Bigalke 2003
    1. Bigalke H, Naumann M. Pharmacology of botulinum neurotoxins. In: Jost WH, editors(s). Botulinum Toxin in Painful Diseases. Pain Headache. Vol. 14. Basel: Karger, 2003:1-13.
Borg‐Stein 2006
    1. Borg-Stein J. Treatment of fibromyalgia, myofascial pain, and related disorders. Physical Medicine and Rehabilitation Clinics of North America 2006;17(2):491-510. [PMID: ] - PubMed
Borodic 2001
    1. Borodic GE, Acquadro M, Johnson EA. Botulinum toxin therapy for pain and inflammatory disorders: mechanisms and therapeutic effects. Expert Opinion on Investigational Drugs 2001;10:1531-44. - PubMed
Brashear 1999
    1. Brashear A, Lew MF, Dykstra DD, Comella CL, Factor SA, Rodnitzky RL. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A–responsive cervical dystonia. Neurology 1999;53:1439-46. - PubMed
Bron 2007
    1. Bron C, Wensing M, Franssen JL, Oostendorp RA. Treatment of myofascial trigger points in common shoulder disorders by physical therapy: a randomised controlled trial [ISRCTN75722066]. BMC Musculoskeletal Disorders 2007;5(8):107. [PMID: ] - PMC - PubMed
Chou 2009
    1. Chou LW, Hsieh YL, Kao MJ, Hong CZ. Remote influences of acupuncture on the pain intensity and the amplitude changes of endplate noise in the myofascial trigger point of the upper trapezius muscle. Archives of Physical Medicine and Rehabilitation 2009;90(6):905-12. [PMID: ] - PubMed
Cork 2004
    1. Cork RC, Isaac I, Elsharydah A, Saleemi S, Zavisca F, Alexander L. A comparison of the verbal rating scale and the visual analog scale for pain assessment. The Internet Journal of Anesthesiology 2004;8(1):1.
Daoust 2008
    1. Daoust R, Beaulieu P, Manzini C, Chauny JM, Lavigne G. Estimation of pain intensity in emergency medicine: a validation study. Pain 2008;138(3):565-70. - PubMed
Dundar 2007
    1. Dundar U, Evcik D, Samli F, Pusak H, Kavuncu V. The effect of gallium arsenide aluminium laser therapy in the management of cervical myofascial pain syndrome: a double blind, placebo-controlled study. Clinical Rheumatology 2007;26(6):930-4. [PMID: ] - PubMed
Edwards 2005
    1. Edwards J. The importance of postural habits in perpetuating myofascial trigger point pain. Acupuncture in Medicine: Journal of the British Medical Acupuncture Society 2005;23(2):77-82. [PMID: ] - PubMed
Ernberg 2002
    1. Ernberg M. The physiopathological mechanisms behind chronic myofacial pain. Lakartidningen 2002;99(32-3):3206-10. [PMID: ] - PubMed
Esenyel 2000
    1. Esenyel M, Caglar N, Aldemir T. Treatment of myofascial pain. American Journal of Physical Medicine and Rehabilitation 2000;79(1):48-52. - PubMed
Fishbain 1986
    1. Fishbain DA, Goldberg M, Meagher BR, Steele R, Rosomoff H. Male and female chronic pain patient's categories by DSM-III psychiatric diagnostic criteria. Pain 1986;26:181-97. - PubMed
Flor 1993
    1. Flor H, Birbaumer N. Comparison of the efficacy of electromyographic biofeedback, cognitive-behavioral therapy, and conservative medical interventions in the treatment of chronic musculoskeletal pain. Journal of Consulting and Clinical Psychology 1993;61(4):653-8. - PubMed
Fricton 1985
    1. Fricton JR, Kroening R, Haley D, Siegert R. Myofascial pain syndrome of the head and neck: a review of clinical characteristics of 164 patients. Oral Surgery 1985;60:615-23. - PubMed
Fricton 1994
    1. Fricton J. Myofascial pain. Baillière's Clinical Rheumatology 1994;8(4):857-80. - PubMed
Gerwin 1995
    1. Gerwin RD. A study of 96 subjects examined both for fibromyalgia and myofascial pain [Abstract]. Journal of Musculoskeletal Pain 1995;3 Suppl 1:121.
Guststein 1938
    1. Guststein M. Diagnosis and treatment of muscular rheumatism. British Journal of Physical Medicine 1938;1:302-21.
Han 1997
    1. Han SC, Harrison P. Myofascial pain syndrome and trigger-point management. Regional Anesthesia 1997;22(1):89-101. [PMID: ] - PubMed
Hanten 2000
    1. Hanten WP, Olson SL, Butts NL, Nowicki AL. Effectiveness of a home program of ischemic pressure followed by sustained stretch for treatment of myofascial trigger points. Physical Therapy 2000;80(10):997-1003. [PMID: ] - PubMed
Higgins 2003
    1. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analysis. BMJ (Clinical Research Ed.) 2003;327:555-7. - PMC - PubMed
Higgins 2008
    1. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 [updated February 2008]. The Cochrane Collaboration, 2008. Available from www.cochrane-handbook.org.
Hollen 2005
    1. Hollen PJ, Gralla RJ, Kris MG, McCoy S, Donaldson GW, Moinpour CM. A comparison of visual analogue and numerical rating scale formats for the Lung Cancer Symptom Scale (LCSS): does format affect patient ratings of symptoms and quality of life? Quality of Life Research 2005;14(3):837-47. [DOI: 10.1007/s11136-004-0833-8] - DOI - PubMed
Hong 1994
    1. Hong CZ. Lidocaine injection versus dry needling to myofascial trigger point - the importance of the local twitch response. American Journal of Physical Medicine and Rehabilitation 1994;73(4):256-63. - PubMed
Howard 2002
    1. Smith HS, Audette J, Royal MA. Botulinum toxin in pain management of soft tissue syndromes. Clinical Journal of Pain 2002;18(6):S147-54. [PMID: ] - PubMed
Hubbard 1993
    1. Hubbard DR, Berkoff GM. Myofascial trigger points show spontaneous needle EMG activity. Spine 1993;18:1803–7. - PubMed
Kam 2002
    1. Kam E, Eslick G, Campbell I. An audit of the effectiveness of acupuncture on musculoskeletal pain in primary health care. Acupuncture in Medicine: Journal of the British Medical Acupuncture Society 2002;20(1):35-8. [PMID: ] - PubMed
Kern 2004
    1. Kern U, Martin C, Scheicher S, Müller H. Does botulinum toxin A make prosthesis use easier for amputees? Journal of Rehabilitation Medicine 2004;36(5):238-9. [PMID: ] - PubMed
Langevin 2011
    1. Langevin P, Peloso PMJ, Lowcock J, Nolan M, Weber J, Gross A, et al. Botulinum toxin for subacute/chronic neck pain. Cochrane Database of Systematic Reviews 2011, Issue 7. Art. No: CD008626. [DOI: 10.1002/14651858.CD008626] - DOI - PubMed
Laskin 1969
    1. Laskin DM. Etiology of the pain-dysfunction syndrome. Journal of the American Dental Association 1969;79:147-53. - PubMed
Lew 2002
    1. Lew MF. Review of the FDA-approved uses of botulinum toxins, including data suggesting efficacy in pain reduction. Clinical Journal of Pain 2002;18(6):S142-6. [PMID: ] - PubMed
Lin 2003
    1. Lin TY. Evaluation of a multidisciplinary educational program in patients with disorders musculoskeletal related work (MSDs) [Avaliação de um Programa Educacional Multidisciplinar em Doentes com Dísturbios Ósteo-musculares Relacionados ao trabalho (DORT)]. PhD thesis presented at the Faculty of Medicine of the University of São Paulo 2003.
McMillan 1997
    1. McMillan AS, Nolan A, Kelly PJ. The efficacy of dry needling and procaine in the treatment of myofascial pain in the jaw muscles. Journal of Orofacial Pain 1997;11:307-14. - PubMed
Peloso 2007
    1. Peloso PMJ, Gross A, Haines T, Trinh K, Goldsmith CH, Burnie SJ. Medicinal and injection therapies for mechanical neck disorders. Cochrane Database of Systematic Reviews 2007, Issue 3. Art. No: CD000319. [DOI: 10.1002/14651858.CD000319.pub4] - DOI - PubMed
Pereda 2006
    1. Pereda CA, Jaeger JU, Carmona L. Systematic review: can botulinum toxin be recommended as treatment for pain in myofascial syndrome? [Revisión sistemática: es recomendable el empleo de toxina botulínica como tratamiento del dolor en el síndrome miofascial?]. Systematic Review 2006;2(4):173-82. - PubMed
Pettengill 1997
    1. Pettengill CA, Reisner-Keller L. The use of tricyclic antidepressants for the control of chronic orofacial pain. Cranio 1997;15(1):53-6. [PMID: ] - PubMed
Reilich 2003
    1. Reilich P, Pongratz D. Myofascial pain syndrome. In: Jost WH, editors(s). Botulinum Toxin in Painful Diseases. Pain Headache. Vol. 14. Basel: Karger, 2003:23-41.
RevMan 2012 [Computer program]
    1. The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2012.
Roth 1998
    1. Roth RS, Horowitz K, Bachman JE. Chronic myofascial pain: knowledge of diagnosis and satisfaction with treatment. Archives of Physical Medicine and Rehabilitation 1998;79(8):966-70. [PMID: ] - PubMed
Royal 2001
    1. Royal MA, Gunyea I, Bhakta B, Mowa V, Ward S, Jenson M. Botulinum toxin type A in the treatment of refractory myofascial pain. Neurology 2001;56 Suppl 3:A350.
Schiffman 1990
    1. Schiffman EL, Fricton JR, Haley DP, Shapiro BL. The prevalence and treatment needs of subjects with temporomandibular disorders. Journal of the American Dental Association 1990;120:295-303. - PubMed
Sellin 1981
    1. Sellin LC, Thesleff S. Pre- and post-synaptic actions of botulinum toxin at the rat neuromuscular junction. Journal of Physiology 1981;317:487-95. [PMID: ] - PMC - PubMed
Silberstein 2000
    1. Silberstein S, Mathew N, Saper J, Jenkins S. Botulinum toxin type A as a migraine preventive treatment. For the BOTOX Migraine Clinical Research Group. Headache 2000;40(6):445–50. - PubMed
Simons 1976
    1. Simons DG. Muscle pain syndromes. Part II. American Journal of Physical Medicine 1976;55(1):15-42. - PubMed
Simons 1996
    1. Simons DG. Clinical and etiological update of myofascial pain from trigger points. Journal of Musculoskeletal Pain 1996;4(1-2):93-121.
Simons 1999
    1. Simons DG, Travell JG, Simons LS. Travell and Simons' Myofascial Pain and Dysfunction: The Trigger Point Manual. 2nd edition. Vol. 1: Upper Half of the Body. Baltimore: Lippincott, Williams & Wilkins, 1999.
Simons 2002
    1. Simons DG, Hong CZ, Simons LS. Endplate potentials are common to mid myofascial trigger points. American Journal of Physical Medicine and Rehabilitation 2002;81:212–22. - PubMed
Singer 1997
    1. Singer E, Dionne R. A controlled evaluation of ibuprofen and diazepam for chronic orofacial muscle pain. Journal of Orofacial Pain 1997;11(2):139-46. [PMID: ] - PubMed
Skootsky 1989
    1. Skootsky SA, Jaeger B, Oye RK. Prevalence of myofascial pain in general internal medicine practice. Western Journal of Medicine 1989;151(2):157-60. - PMC - PubMed
Sola 1955
    1. Sola AE, Rodenberg ML, Gettys BB. Incidence of hypersensitive areas in posterior shoulder muscles. American Journal of Physical Medicine 1955;34:585-90. - PubMed
Solberg 1986
    1. Solberg WK. Temporomandibular disorders: masticatory myalgia and its management. British Dental Journal 1986;160:351-6. - PubMed
Srbely 2007
    1. Srbely JZ, Dickey JP. Randomized controlled study of the antinociceptive effect of ultrasound on trigger point sensitivity: novel applications in myofascial therapy? Clinical Rehabilitation 2007;21(5):411-7. [PMID: ] - PubMed
Talaat 1986
    1. Talaat AM, el-Dibany MM, el-Garf A. Physical therapy in the management of myofacial pain dysfunction syndrome. Annals of Otology, Rhinology and Laryngology 1986;95(3 Pt 1):225-8. [PMID: ] - PubMed
Tang 2000
    1. Tang JL, Liu JLY. Misleading funnel plot for detection of bias in meta-analysis. Journal of Clinical Epidemiology 2000;53:477-84. - PubMed
Thornton 2000
    1. Thornton A, Lee P. Publication bias in meta-analysis: its causes and consequences. Journal of Clinical Epidemiology 2000;53:207-16. - PubMed
Travell 1999
    1. Travell D, Simons DG. Myofascial Pain and Dysfunction: the Trigger Point Manual. 2nd edition. Vol. 1: Upper half of the body. Baltimore: Lippincott, Williams & Wilkins, 1999.
Tubergen 2002
    1. Tubergen AV, Debats I, Ryser L, Londoño J, Burgos-Vargas R, Cardiel MH, et al. Use of a numerical rating scale as an answer modality in ankylosing spondylitis–specific questionnaires. Arthritis Care and Research 2002;47(3):242–8. [DOI: 10.1002/art.10397] - DOI - PubMed
Tunks 1999
    1. Tunks E, Crook J. Regional soft tissue pains: alias myofascial pain? Baillières Clinical Rheumatology 1999;13:345–70. - PubMed
Unnebrink 2001
    1. Unnebrink K, Windeler J. Intention-to-treat methods for dealing with missing values in clinical trials of progressively deteriorating diseases. Statistics in Medicine 2001;20:3931-46. - PubMed

Publication types

MeSH terms

Substances